Association of Pre-Transplant Angiopoietin-2 Index with the Risk of Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation

Pre-transplant Angiopoietin-2 İndeksinin Hematopoietik Kök Hücre Transplantasyonu Sonrası Akut Graft Versus Host Hastalığı Riski ile İlişkisi

Özlem Satırer1, İnci Cevher Zeytin2, Berna Alkan2, Jale Karakaya4, Duygu Çetinkaya2,3, Fatma Visal Okur2,3

1Hacettepe University Faculty of Medicine, Department of Pediatrics, Ankara, Turkey
2Hacettepe University, Center for Stem Cell Research and Development (PEDI-STEM), Ankara, Turkey
3Hacettepe University Faculty of Medicine, Department of Pediatrics, Division of Pediatric Hematology and Bone Marrow Transplantation Unit, Ankara, Turkey
4Hacettepe University Faculty of Medicine, Department of Biostatistics, Ankara, Turkey

Abstract

Objective: Angiogenic factors (AFs) released under endothelial stress are reflective of tissue healing, while some may also contribute to tissue damage/inflammation. We investigated whether alterations in the pre-transplant levels of AFs were associated with the risk of acute graft-versus-host disease (aGvHD).

Materials and Methods: The pre-conditioning plasma levels of angiopoietin-2 (Ang2), endoglin, and follistatin were measured for 37 patients together with inflammatory markers. The index values defined were evaluated to better identify the alterations.

Results: The patients had higher pre-conditioning levels of Ang2, endoglin, and follistatin compared to controls. The patients with aGvHD had higher Ang2 index and lower albumin index scores in comparison to those without aGvHD. Multivariate analysis revealed that the pre-transplant Ang2 index was an independent risk factor for aGvHD development.

Conclusion: Pre-transplant evaluation of plasma Ang2 levels along with inflammatory status even before conditioning is associated with endothelial vulnerability. The pre-transplant Ang2 index could be a promising candidate to estimate the risk of aGvHD.

Keywords: Graft-versus-host disease, Angiopoietin-2, Angiogenesis, Inflammation, Hematopoietic stem cell transplantation

Amaç: Endotelyal stres altında salınan anjiyojenik faktörler (AF), doku iyileşmesini yansıtrakken, bazıları doku hasarına/iltihaba katkıda bulunabilir. Bu çalışmamızda pre-transplant AF düzeylerindeki değişikliklerin akut graft versus host hastalığı (aGvHH) riskini jeo etkili olup olmadığını araştırdık.

Gereç ve Yöntemler: Otuz yedi hastada plazma anjiyopoietin-2, endoglin ve follistatin seviyeleri, enfamatuvar belirteçlerine birlikte hazırlanma rejiyeni öncesi değerlendirildi. Tanımlanan indeks değerleri AF düzeylerindeki değişiklikleri daha iyi tespit edebilmek için kullanıldı.

Bulgular: Kontrollere kıyasla hastaların nakil öncesi bakılan Ang2, endoglin ve follistatin seviyeleri daha yüksekti. aGvHH gelişen hastalarda, gelişmemeyenlere kıyasla daha yüksek Ang2 indeks ve daha düşük albümin indeks değerleri saptandı. Çok değişkenli analizler, pre-transplant Ang2 indeksinin aGvHH gelişimi için bağımsız bir risk faktörü olduğunu ortaya koydu.

Sonuç: Plazma Ang2 düzeylerinin nakil öncesi hasta hazırlama rejimi verilmeden önce enfamatuvar durum ile birlikte değerlendirilmesi endotelin hasara yol aç.newBuilder dokundaki bilgi verebili. Pre-transplant Ang2 indeksi, aGvHH riskini tahmin etmek için kullanılabilecek bir belirteç olabilir.

Anahtar Sözcükler: Graft versus host hastalığı, Anjiyopoietin-2, Anjiogenez, Enflammasyon, Hematopoietik kök hücre transplantasyonu
Introduction

Acute graft-versus-host disease (aGvHD) is one of the major complications of allogeneic hematopoietic stem cell transplantation (HSCT) with significant morbidity and mortality [1,2]. Despite the advances in our understanding of the pathogenesis of aGvHD, the mechanisms contributing to the development and severity of aGvHD are not yet fully elucidated [3]. Discovery of biomarkers for aGvHD has provided insight into the complex pathogenesis of aGvHD and suggests novel mechanisms of recipient tissue damage and impaired regenerative capacity for therapeutic targeting [4,5,6,7,8,9]. Recent studies have shown that epithelial cell damage, characteristic of aGvHD, develops secondary to vascular endothelial damage caused by alloreactive donor T cells [10,11]. Endothelial damage leads to endothelial cell activation and stimulates angiogenesis. Angiogenesis contributes to persistent inflammation leading to clinical presentation of aGvHD. This interaction between inflammation and angiogenesis leads to the development of aGvHD as well as other serious early-onset complications of HSCT known as vascular endothelial syndromes [12]. Therefore, it has been suggested that the vascular endothelium may be a target for the early diagnosis and treatment of HSCT complications. Levels of circulating angiogenic factors (AFs) associated with tissue repair, including epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and heparin binding EGF-like growth factor (HB-EGF), have been found to be significantly decreased in patients with aGvHD and steroid-refractory aGvHD compared to patients without aGvHD and those with steroid-responsive aGvHD [1,10,12]. On the other hand, endothelial damage and inflammation-related factors such as angiopoietin-2 (Ang2), soluble endoglin, follistatin, and placental growth factor have been shown to increase significantly in patients with aGvHD and steroid-refractory aGvHD [13,14,15,16,17,18]. Studies investigating the impact of circulating AFs on aGvHD have mostly been focused on the post-transplant period. However, taking into consideration that AF levels, and especially levels of those AFs involved in endothelial damage/inflammation, can provide useful information about endothelial vulnerability to damage, it might be a beneficial approach to assess AF levels during the pre-transplant period [19]. We propose that patients with alterations in circulating AF levels involved in damage or inflammation during the pre-transplant period would have higher risk for the development of aGvHD.

Materials and Methods

This study was approved by the Non-Interventional Ethics Committee of Hacettepe University (reference number: GO 18/235-29). Peripheral blood samples were collected before the conditioning regimen (day -9) and after completion of the conditioning regimen (day 0) prior to transplantation. The levels of Ang2, endoglin, and follistatin were studied from the plasma samples of patients and healthy controls simultaneously by luminex immunoassay method using the Human Premix Multianalyte Kit (R&D Systems, Cat. # LXSAH) and Luminex 200 device. The results were analyzed with the luminex analyzer with the X-Y platform. In addition, serum uric acid, albumin, and C-reactive protein (CRP) levels measured during the pre-transplant period (before and after conditioning regimen) were noted as systemic inflammatory markers for the patients.

Statistical Analysis

Statistical analyses were performed using SPSS 22.0 software (IBM Corp.). The risk factors for aGvHD were examined by logistic regression analysis. Receiver operating characteristic (ROC) curves were constructed for the significant indices predicting the incidence of aGvHD, and the area under the ROC curve (AUC) was calculated to examine index performance.

Results

Thirty-seven patients (19 male and 18 female patients; median age: 6 years, range: 1-22 years) were included in the study. Seven out of 37 patients underwent allogeneic bone marrow transplantation for non-malignant hematologic diseases (severe aplastic anemia and thalassemia), 13 patients for hematologic malignancies, 14 patients for primary immunodeficiency disorders, and 3 patients for neurometabolic disorders. Overall, 24 (65%) of 37 patients had non-malignant disorders and 13 (35%) had hematologic malignancies. All patients were transplanted from a fully HLA-matched sibling or family donor except one patient who received a bone marrow graft from a partially matched family donor. As the stem cell source, bone marrow was used for 34 (92%) patients, while peripheral blood was preferred for 3 patients. Among the 37 patients, 33 (89%) received a busulfan-based or total body irradiation-based myeloablative conditioning regimen. All patients received cyclosporin and low-dose methotrexate for GVHD prophylaxis. Upon successful engraftment in all patients, 16 patients were diagnosed with aGvHD (43%), whereas only one patient was diagnosed with chronic GVHD. Fifteen out of 16 patients with aGvHD had mild to moderate aGvHD and only one patient had severe aGvHD. Skin findings were reported in 15 patients, liver findings in 5 patients, and gastrointestinal system findings in 3 patients. Seven of 16 patients with aGvHD had a history of engraftment syndrome and 6 patients had a history of hepatic veno-occlusive disease.

First, we compared the pre-conditioning plasma levels of Ang2, endoglin, and follistatin of the 37 patients with the levels of 10 healthy controls. The patients showed significantly increased levels of all three AFs associated with damage and inflammation (Ang2, 2738.3±367 pg/mL vs. 867.5±151 pg/mL, p<0.001; endoglin, 2149±215 pg/mL vs. 1166.5±239 pg/mL, p<0.001; follistatin, 2149±215 pg/mL vs. 1166.5±239 pg/mL, p<0.001). The area under the ROC curve (AUC) was calculated to examine index performance.
mL, p=0.008; follistatin, 12200.4±1093 pg/mL vs. 5832.9±732 pg/mL, p<0.001). Interestingly, the difference between the Ang2 and endoglin levels of patients and controls disappeared after conditioning; only the follistatin levels remained higher in the patients (11502.6±772 pg/mL vs. 5832.9±732 pg/mL, p<0.001). Next, pre- and post-conditioning serum uric acid, albumin, and CRP levels were evaluated. Significant elevations in serum uric acid (2.47±0.2 mg/dL vs. 6.64±0.4 mg/dL, p<0.001) and CRP (1.77±1.2 mg/dL vs. 8.14±0.7 mg/dL, p<0.001) levels were observed after conditioning, while albumin (3.78±0.1 g/dL vs. 2.9±0.1 g/dL, p<0.001) decreased in all patients. In order to eliminate the effects of inter-patient variations in AF levels, and to better evaluate the changes in AF levels after conditioning, the index value for each marker was calculated as the ratio of the pre-conditioning levels to post-conditioning levels. Patients with and without aGvHD were compared according the index values of the parameters that showed significant changes after conditioning (Ang2, endoglin, follistatin, uric acid, albumin, and CRP). The Ang2 index was higher (2.56 vs. 1.81, p=0.028) and the albumin index was lower (1.19 vs. 1.41, p=0.017) in the patients with aGvHD compared to the patients without aGvHD. The other indices studied did not reveal any significant alterations between the groups (Table 1). This result suggests a relationship between pre-transplant Ang2 levels and aGvHD.

We conducted univariable and multivariable logistic regression analyses to identify significant AFs and/or other inflammatory markers’ index values that would be indicative of an increased risk for aGvHD (Table 2). Accordingly, we demonstrated that the pre-transplant Ang2 index was an independent risk factor for aGvHD development (p=0.04, odds ratio: 2.25, 95% confidence interval: 1.03-4.9). In addition, a low pre-transplant albumin index and the diagnosis of hematologic malignancy conferred higher risk of aGvHD (p<0.05). ROC curve analysis was then performed to determine the cutoff and assess the predictive value of the pre-transplant Ang2 index for aGvHD. As shown in Table 3, the cutoff of the Ang2 index in the pre-transplant period for aGvHD was 1.44 with an AUC of 72%, sensitivity of 100%, and specificity of 45%. We observed a difference in the frequency of aGvHD among the patients when compared regarding the Ang2 index cutoff value (above the cutoff: 57%.

| Table 1. Comparison of index values of plasma angiogenic factors and inflammatory markers of patients with and without acute graft-versus-host disease (aGvHD). |
|-----------------|-----------------|-----------------|-----------------|
| **Index**, median (range) | Present | Absent | p  |
| Angiopoietin-2*** | 2.56 (1.52-13.6) | 1.81 (0.53-3.81) | 0.028 |
| Endoglin** | 1.29 (0.53-3.13) | 1.38 (0.48-2.82) | 0.63 |
| Follistatin*** | 0.97 (0.46-3.39) | 1.08 (0.43-2.30) | 0.86 |
| Uric acid*** | 0.42 (0.12-1.27) | 0.35 (0.12-0.79) | 0.26 |
| Albumin ** | 1.19 (0.72-1.66) | 1.41 (0.91-2.14) | 0.17 |
| C-reactive protein*** | 0.22 (0.04-0.48) | 0.23 (0.02-0.60) | 0.98 |

*Index value: pre-conditioning plasma level/post-conditioning plasma level.
**The t-test was performed in independent groups.
*** Mann-Whitney U test in independent groups. Values of p<0.05 were considered statistically significant.

| Table 2. Multivariable logistic regression model for acute graft-versus-host disease. |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Parameters | p | Odds ratio | Odds ratio, 95% confidence interval |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| | | Minimum | Maximum |
| Primary disease (malignant/non-malignant) | 0.032 | 9.716 | 1.214 | 77.747 |
| Angiopoietin-2 index | 0.043 | 2.245 | 1.027 | 4.905 |
| Albumin index | 0.025 | 0.016 | 0.001 | 0.586 |
| Constant | 0.138 | 41.593 |

| Table 3. Optimal threshold for the pre-transplant angiopoietin-2 (Ang2) index for predicting acute graft-versus-host disease. |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| **Index** (pre-/post-conditioning value) | Area under the curve | Cutoff point | Sensitivity (%) | Specificity (%) |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Ang2 | 0.716 | 1.44 | 100 | 45 |
Our results suggest that pre-transplant evaluation of plasma Ang2 levels along with inflammatory status even before conditioning might be a reliable indicator of endothelial vulnerability. The pre-transplant Ang2 index as an independent risk factor for aGVHD seems to be a promising candidate for estimating the risk of aGVHD in allogeneic HSCT recipients. However, there is still a need for mechanistical studies to understand the precise role of angioregulatory factors in the pathogenesis of aGVHD.

**Ethics**

**Ethics Committee Approval:** This study was approved by the Non-Interventional Ethics Committee of Hacettepe University (reference number: GO 18/235-29).

**Authorship Contributions**

Concept: F.V.O., D.C.; Design: F.V.O., D.C.; Data Collection or Processing: Ö.S., D.C.; Analysis or Interpretation: Ö.S., İ.C.Z., B.A.; Writing: Ö.S., İ.C.Z., B.A., J.K., D.C., F.V.O.

Conflict of Interest: No conflict of interest was declared by the authors.

**Financial Disclosure:** This study was supported by the Hacettepe University Scientific Research Projects Coordination Unit (project number: THD-2019-17870).

**References**

1. Magenau J, Runaas L, Reddy P. Advances in understanding the pathogenesis of graft-versus-host disease. Br J Haematol 2016;173:190-205.

2. Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD, Zhang MJ, Antin JH, Bolwell BJ, Bredeson C, Cahn JY, Cairo M, Gale RP, Gupta V, Lee SJ, Litzow M, Weisdorf DJ, Horowitz MM, Hahn T. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012;119:296-307.

3. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012;12:443-458.

4. He FC, Holtan SG. Biomarkers in graft-versus-host disease: from prediction and diagnosis to insights into complex graft/host interactions. Curr Hematol Malig Rep 2018;13:44-52.

5. Paczesny S. Biomarkers for posttransplantation outcomes. Blood 2018;131:2193-2204.

6. McDonald GB, Tabellini L, Storer BE, Lawler RL, Martin PJ, Hansen JA. Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment. Blood 2015;126:113-120.

7. Dietrich S, Falk CS, Benner A, Karamustafa S, Hahn E, Andruulis M, Hegenhart U, Ho AD, Dreger P, Luft T. Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment. Biol Blood Marrow Transplant 2013;19:22-27.

8. Balakrishnan B, Illangeswaran RSS, Rajamani BM, Pai AA, Raj IX, Paul DZ, Lakshmi K, Mani T, Mohanan E, Kulkarni U, Devasia AJ, Fouzia NA, Korula A, Abraham A, Srivastava A, Mathews V, Paczesny S, George B, Balasubramanian P. Prognostic plasma biomarkers of early complications and graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation. EJHaem 2020;1:219-229.
9. Major-Monfried H, Renteria AS, Pawarode A, Reddy P, Ayuk F, Holler E, Efebera YA, Hogan WJ, Wolff M, Qayed M, Henxer EO, Wuhliham K, Ordemann R, Young R, Shah J, Hartwell MJ, Chaudhry MS, Aziz M, Etra A, Yanik GA, Kröger N, Weber D, Chen YB, Nakamura R, Rössler W, Kitko CL, Harris AC, Pulsipher M, Reshef R, Kowalys G, Morales G, Torres I, Özbek U, Ferrara JLM, Levine JE. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood 2018;131:2846–2855.

10. Carreras E, Diaz-Ricart M. Early complications of endothelial origin. In: Kröger ECDM (ed). The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. Cham, Springer, 2019.

11. Ali AM, DiPersio JF, Schroeder MA. The role of biomarkers in the diagnosis and risk stratification of acute graft-versus-host disease: a systematic review. Biol Blood Marrow Transplant 2016;22:1552–1564.

12. Carreras E, Diaz-Ricart M. The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transplant 2011;46:1495–1502.

13. Holtan SG, Arora M. Angiogenic factors and inflammation in steroid-refractory acute graft-vs-host disease. Transfus Med Rev 2016;167:80–87.

14. Tateda K, Kohno A, Ozeki K, Watamoto K, Ueda N, Yamaguchi Y, Kobayashi T, Yokota I, Teramukai S, Taniwaki M, Kuroda J, Morishita Y. A novel diagnostic and prognostic biomarker panel for endothelial cell damage-related complications in allogeneic transplantation. Blood Marrow Transplant 2016;22:1573–1581.

15. Blix ES, Husebekk A. Raiders of the lost mark - endothelial cells and their role in transplantation for hematologic malignancies. Leuk Lymphoma 2016;57:2752–2762.

16. Lindas R, Tvedt TH, Hatfield KJ, Reikvam H, Bruserud O. Preconditioning serum levels of endothelial cell-derived molecules and the risk of posttransplant complications in patients treated with allogeneic stem cell transplantation. J Transplant 2014;2014:404096.

17. Min CK, Kim SY, Lee MJ, Eom KS, Kim YJ, Kim HJ, Lee S, Cho SG, Kim DW, Lee JW, Kim WS, Kim CC, Cho CS. Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation. Bone Marrow Transplant 2006;38:149–156.

18. Porkholm M, Bono P, Saarinen-Pihkala UM, Kivivuori SM. Higher angiopoietin-2 and VEGF levels predict shorter EFS and increased nonrelapse mortality after pediatric hematopoietic SCT. Bone Marrow Transplant 2013;48:50–55.

19. Riesner K, Shi Y, Jacobi A, Kräuter M, Kaluwa M, McGarey A, Mertlitz S, Cordes S, Schrezenmeier JF, Mengwasser J, Westphal J, Perez-Hernandez D, Schmitt C, Dittmar G, Penack O, Socié G, van den Brink MR. The importance of neovascularization and its inhibition for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2009;45:613–615.

20. Panoskaltsis-Mortari A, Weisdorf DJ, Slungaard A, MacMillan ML, Cooley SA, Blazar BR, Holtan SG, Verneris MR, Schultz KR, Newell LF, Meyers G, He F, Defor TE, Vercellotti GM, Slungaard A, MaCorral BA, Blazar BR, Panoskaltsis-Mortari A, Weisdorf DJ. Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802. Biol Blood Marrow Transplant 2015;21:1029–1036.

21. Chaidos A, Kaner E, Appleroy JF. Risk assessment in haematopoietic stem cell transplantation: disease and disease stage. Best Pract Res Clin Haematol 2007;20:125–154.

22. Reikvam H, Mosevoll KA, Melve G, Guttner CC, Sjo M, Bentsen PT, Bruserud O. The pretransplantation serum cytokine profile in allogeneic stem cell recipients differs from healthy individuals, and various profiles are associated with different risks of posttransplantation complications. Biol Blood Marrow Transplant 2012;18:190–199.

23. Gratzolz A, Assman K, Badmungo H, Orchard K, Kröger N, Snowden JA; Joint Accreditation Committee of the European Society for Blood and Marrow Transplantation (EBMT). Conditioning intensity before allogeneic hematopoietic stem cell transplantation: a quality control audit. Br J Haematol 2021;192:e151–e154.

24. de Kretser DM, O’Hehir RE, Hardy CL, Hedger MP. The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair. Mol Cell Endocrinol 2012;359:101–106.

25. Palomo M, Diaz-Ricart M, Carbo C, Rovira M, Fernandez-Aviles F, Escolar G, Eissner G, Holler E, Carreras E. The release of soluble factors contributing to endothelial activation and damage after hematopoietic stem cell transplantation is not limited to the allogeneic setting and involves several pathogenic mechanisms. Blood 2011;117:537–546.

26. Penack O, Socié G, van den Brink MR. The importance of neovascularization and its inhibition for allogeneic hematopoietic stem cell transplantation. Blood 2011;117:4181–4189.

27. Fieler U, Reiss Y, Scharfeneccker M, Grunow V, Koidl S, Thurston G, Gale NW, Witserezath M, Rosseau S, Suttrop N, Sokbe A, Herrmann M, Preissner KT, Vajkoczky P, Augustin HG. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006;12:235–239.

28. Kreuter M, Kropff MF, Fischaleck A, Junker K, Gens J, Heinmeier A, Lindemann M, Reinmuth N, Berdel WE, Mesters RM, Thomas M. Prognostic relevance of angiogenesis in stage III NSCLC receiving modality treatment. Eur Respir J 2009;33:1383–1388.

29. Nomura S, Ishii K, Inami N, Kimura Y, Yoshimura N, Ishida H, Yoshihara T, Urase F, Maeda Y, Hayashi K. Evaluation of angiopoietins and cell-derived microparticles after stem cell transplantation. Biol Blood Marrow Transplant 2008;14:766–774.